<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2023-339-348</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3361</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Гиперлептинемия как маркер различных фенотипов избыточного веса у женщин с ревматоидным артритом и системной красной волчанкой</article-title><trans-title-group xml:lang="en"><trans-title>Hyperleptinemia as a marker of various phenotypes of obesity and overweight in women with rheumatoid arthritis and systemic lupus erythematosus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1147-5936</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кондратьева</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kondrateva</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">kondratyeva.liubov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2024-6927</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горбунова</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorbunova</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1053-6952</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панафидина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Panafidina</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5793-4689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попкова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popkova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2023</year></pub-date><volume>61</volume><issue>3</issue><elocation-id>339–348</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Кондратьева Л.В., Горбунова Ю.Н., Панафидина Т.А., Попкова Т.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Кондратьева Л.В., Горбунова Ю.Н., Панафидина Т.А., Попкова Т.В.</copyright-holder><copyright-holder xml:lang="en">Kondrateva L.V., Gorbunova Y.N., Panafidina T.A., Popkova T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3361">https://rsp.mediar-press.net/rsp/article/view/3361</self-uri><abstract><p>Цель исследования – выделить различные фенотипы избыточного веса у женщин с системной красной волчанкой (СКВ) и ревматоидным артритом (РА) на основании индекса массы тела (ИМТ) и уровня лептина в сыворотке крови, а также уточнить частоту различных метаболических нарушений, артериальной гипертензии (АГ) и сердечно-сосудистых осложнений (ССО) при отдельных фенотипах. Материал и методы. В исследование включены 50 женщин с РА и 46 – с СКВ в возрасте от 18 до 65 лет без сахарного диабета в анамнезе и гипергликемии натощак. У всех пациентов определяли концентрацию лептина (иммуноферментный анализ), инсулина (электрохемилюминисцентный анализ), рассчитывали индекс HOMA-IR. Гиперлептинемию диагностировали при концентрации лептина &gt;11,1 нг/мл, инсулинорезистентность (ИР) – при значениях HOMA-IR≥2,77. Выделяли три основных фенотипа избыточного веса: «классический» (ИМТ≥25 кг/м2  + гиперлептинемия); «здоровый» (ИМТ≥25 кг/м2 , без гиперлептинемии); «скрытый» или «латентный» (ИМТ&lt;25 кг/м2  + гиперлептинемия), а также «нормальный вес» (ИМТ&lt;25 кг/м2 , без гиперлептинемии). Результаты. Больные РА и СКВ были сопоставимы по возрасту (p=0,4), длительности заболевания (р=0,2) и ИМТ (р=0,5). Гиперлептинемия обнаружена у 46% женщин при РА и у 74% при СКВ (р=0,005), ИР – у 10% и 22% пациентов соответственно (р=0,2). «Классический» фенотип избыточного веса был диагностирован в 30%, «здоровый» – в 8%, «скрытый» – в 16% случаев при РА; при СКВ – в 44%, 0% и 30% случаев соответственно. ИР обнаружена у 3%, АГ – у 6% больных с «нормальным весом». При «классическом» фенотипе ИР (29%) и АГ (66%) встречались чаще, чем при «нормальном весе» (p&lt;0,01 во всех случаях); при «скрытом» фенотипе статистически значимые различия отмечались только по частоте АГ (45%; р=0,0012), но не ИР (18%). 3 из 4 женщин с ССО в анамнезе имели «классический» избыточный вес, одна пациентка – «нормальный вес». Заключение. У женщин с СКВ до 65 лет частота гиперлептинемии, но не ИР, выше, чем у больных РА. При обоих заболеваниях наиболее часто встречается «классический» фенотип избыточного веса. При РА реже, чем при СКВ, обнаруживали «скрытый» фенотип, в то же время «здоровый» фенотип для СКВ не характерен. Частота метаболических нарушений и АГ низкая при «нормальном весе» и «здоровом» фенотипе, высокая – при «классическом», промежуточная – при «скрытом» фенотипе.</p></abstract><trans-abstract xml:lang="en"><p>Objective – to identify different phenotypes of overweight in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) based on body mass index (BMI) and serum leptin levels, as well as to determine the frequencies of various metabolic disorders, hypertension and cardiovascular complications in individual phenotypes. Material and methods. The study included 50 women with RA and 46 with SLE aged 18 to 65 years without a history of diabetes and fasting hyperglycemia. The concentration of leptin (ELISA), insulin (electrochemiluminescence analysis) was determined in all patients, and the HOMA-IR index was calculated. Hyperleptinemia was diagnosed at leptin concentrations &gt;11,1 ng/ml, insulin resistance (IR) – at HOMA-IR values ≥2,77. Three main phenotypes of overweight were distinguished: “classic” (BMI≥25 kg/m2  + hyperleptinemia), “healthy” (BMI≥25 kg/m2 , without hyperleptinemia), “hidden” or “latent” (BMI&lt;25 kg/m2  + hyperleptinemia), as well as “normal weight” (BMI&lt;25 kg/m2 , without hyperleptinemia). Results. Patients with RA and SLE were similar in age (p=0.4), disease duration (p=0.2) and BMI (p=0.5). Hyperleptinemia was found in 46% of women with RA and 74% – with SLE (p=0.005), IR – in 10% and 22% of patients, respectively (p=0.2). The “classic” phenotype of overweight was diagnosed in 30%, “healthy” – in 8%, “hidden” – in 16% of cases with RA and in 44%, 0% and 30% of cases with SLE, respectively. IR was found in 3%, hypertension – in 6% of patients with “normal weight”. With the “classical” phenotype, IR (29%) and hypertension (66%) were more common than with “normal weight” (p&lt;0.01 in all cases), with the “hidden” phenotype, significant differences were obtained only in hypertension frequency (45%; p=0.0012), but not IR (18%). 3 out of 4 women with a history of cardiovascular complications suffered from “classic” overweight, one patient had a “normal weight”. Conclusion. In women with SLE up to 65 years of age, the frequency of hyperleptinemia, but not IR, is higher than in patients with RA. In both diseases, the “classic” overweight phenotype is most common. In RA, a “hidden” phenotype was detected less often than in SLE, at the same time, a “healthy” phenotype is not characteristic of SLE. The frequencies of metabolic disorders and hypertension is low with the “normal weight” and “healthy” phenotype, high – with the “classic”, intermediate – with the “hidden” phenotype.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>системная красная волчанка</kwd><kwd>фенотипы</kwd><kwd>ожирение</kwd><kwd>избыточный вес</kwd><kwd>индекс массы тела</kwd><kwd>лептин</kwd><kwd>гиперлептинемия</kwd><kwd>инсулинорезистентность</kwd><kwd>HOMA-IR</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>systemic lupus erythematosus</kwd><kwd>phenotypes</kwd><kwd>obesity</kwd><kwd>overweight</kwd><kwd>body mass index</kwd><kwd>leptin</kwd><kwd>hyperleptinemia</kwd><kwd>insulin resistance</kwd><kwd>HOMA-IR</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена за счет средств бюджетного финансирования на выполнение государственного задания по теме «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний» (регистрационный номер 1021051402790-6).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. doi: 10.1136/ard.2010.135871</mixed-citation><mixed-citation xml:lang="en">Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-487. doi: 10.1136/ard.2010.135871</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Baker JF, Billig E, Michaud K, Ibrahim S, Caplan L, Cannon GW, et al. Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(7):1711-1717. doi: 10.1002/art.39136</mixed-citation><mixed-citation xml:lang="en">Baker JF, Billig E, Michaud K, Ibrahim S, Caplan L, Cannon GW, et al. Weight loss, the obesity paradox, and the risk of death in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(7):1711-1717. doi: 10.1002/art.39136</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450-3457. doi: 10.1002/art.20612</mixed-citation><mixed-citation xml:lang="en">Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450-3457. doi: 10.1002/art.20612</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Santos MJ, Vinagre F, Canas da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29(3):470-476.</mixed-citation><mixed-citation xml:lang="en">Santos MJ, Vinagre F, Canas da Silva J, Gil V, Fonseca JE. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of Caucasian female patients. Clin Exp Rheumatol. 2011;29(3):470-476.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(2):261-268. doi: 10.1002/acr.20343</mixed-citation><mixed-citation xml:lang="en">Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(2):261-268. doi: 10.1002/acr.20343</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Elkan AC, Engvall IL, Cederholm T, Hafström I. Rheumatoid cachexia, central obesity and malnutrition in patients with lowactive rheumatoid arthritis: Feasibility of anthropometry, mini nutritional assessment and body composition techniques. Eur J Nutr. 2009;48(5):315-322. doi: 10.1007/s00394-009-0017-y</mixed-citation><mixed-citation xml:lang="en">Elkan AC, Engvall IL, Cederholm T, Hafström I. Rheumatoid cachexia, central obesity and malnutrition in patients with lowactive rheumatoid arthritis: Feasibility of anthropometry, mini nutritional assessment and body composition techniques. Eur J Nutr. 2009;48(5):315-322. doi: 10.1007/s00394-009-0017-y</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Сорокина АО, Демин НВ, Добровольская ОВ, Никитинская ОА, Торопцова НВ, Феклистов АЮ. Патологические фенотипы состава тела у больных ревматическими заболеваниями. Научно-практическая ревматология. 2022;60(4):487-494. doi: 10.47360/1995-4484-2022-487-494</mixed-citation><mixed-citation xml:lang="en">Sorokina AO, Demin NV, Dobrovolskaya OV, Nikitinskaya OA, Toroptsova NV, Feklistov AYu. Pathological phenotypes of body composition in patients with rheumatic diseases. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):487-494 (In Russ.). doi: 10.47360/1995-4484-2022-487-494</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714-724. doi: 10.1016/S2213-8587(18)30137-2</mixed-citation><mixed-citation xml:lang="en">Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714-724. doi: 10.1016/S2213-8587(18)30137-2</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kim NH, Kim KJ, Choi J, Kim SG. Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical co ronavirus disease 2019 outcomes than metabolically healthy individuals without obesity. Metabolism. 2022;128:154894. doi: 10.1016/j.metabol.2021.154894</mixed-citation><mixed-citation xml:lang="en">Kim NH, Kim KJ, Choi J, Kim SG. Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical co ronavirus disease 2019 outcomes than metabolically healthy individuals without obesity. Metabolism. 2022;128:154894. doi: 10.1016/j.metabol.2021.154894</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Stefan N. Metabolically healthy and unhealthy normal weight and obesity. Endocrinol Metab (Seoul). 2020;35(3):487-493. doi: 10.3803/EnM.2020.301</mixed-citation><mixed-citation xml:lang="en">Stefan N. Metabolically healthy and unhealthy normal weight and obesity. Endocrinol Metab (Seoul). 2020;35(3):487-493. doi: 10.3803/EnM.2020.301</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617-1624. doi: 10.1001/archinte.168.15.1617</mixed-citation><mixed-citation xml:lang="en">Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617-1624. doi: 10.1001/archinte.168.15.1617</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто ЕВ, Недогода СВ, Конради АО, Баранова ЕИ, Фомин ВВ, Верткин АЛ, и др. Концепция новых национальных клинических рекомендаций по ожирению. Российский кардиологический журнал. 2016;(4):7-13. doi: 10.15829/1560-4071-2016-4-7-13</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Nedogoda SV, Konradi AO, Baranova EI, Fomin VV, Vertkin AL, et al. The concept of novel national clinical guidelines on obesity. Russian Journal of Cardiology. 2016;(4):7-13 (In Russ.). doi: 10.15829/1560-4071-2016-4-7-13</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Giraud C, Lambertc C, Dutheild F, Pereirac B, Soubriera M, Tournadre A. The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis. Joint Bone Spine. 2021;88(1):105059. doi: 10.1016/j.jbspin.2020.07.008</mixed-citation><mixed-citation xml:lang="en">Giraud C, Lambertc C, Dutheild F, Pereirac B, Soubriera M, Tournadre A. The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis. Joint Bone Spine. 2021;88(1):105059. doi: 10.1016/j.jbspin.2020.07.008</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Frithioff-Bøjsøe C, Lund MAV, Lausten-Thomsen U, Hedley PL, Pedersen O, Christiansen M, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes. 2020;21(2):194-202. doi: 10.1111/pedi.12964</mixed-citation><mixed-citation xml:lang="en">Frithioff-Bøjsøe C, Lund MAV, Lausten-Thomsen U, Hedley PL, Pedersen O, Christiansen M, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes. 2020;21(2):194-202. doi: 10.1111/pedi.12964</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bungau S, Behl T, Tit DM, Banica F, Bratu OG, Diaconu CC, et al. Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD. Exp Ther Med. 2020;20(6):197. doi: 10.3892/etm.2020.9327</mixed-citation><mixed-citation xml:lang="en">Bungau S, Behl T, Tit DM, Banica F, Bratu OG, Diaconu CC, et al. Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD. Exp Ther Med. 2020;20(6):197. doi: 10.3892/etm.2020.9327</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39(7):1176-1188. doi: 10.1038/aps.2018.40</mixed-citation><mixed-citation xml:lang="en">Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39(7):1176-1188. doi: 10.1038/aps.2018.40</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bell BB, Rahmouni K. Leptin as a mediator of obesity-induced hypertension. Curr Obes Rep. 2016;5(4):397-404. doi: 10.1007/s13679-016-0231-x</mixed-citation><mixed-citation xml:lang="en">Bell BB, Rahmouni K. Leptin as a mediator of obesity-induced hypertension. Curr Obes Rep. 2016;5(4):397-404. doi: 10.1007/s13679-016-0231-x</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Farcaş AD, Rusu A, Stoia MA, Vida-Simiti LA. Plasma leptin, but not resistin, TNF-α and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease. Cytokine. 2018;103:46-49. doi: 10.1016/j.cyto.2018.01.002</mixed-citation><mixed-citation xml:lang="en">Farcaş AD, Rusu A, Stoia MA, Vida-Simiti LA. Plasma leptin, but not resistin, TNF-α and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease. Cytokine. 2018;103:46-49. doi: 10.1016/j.cyto.2018.01.002</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Csongrádi É, Káplár M, Nagy B Jr, Koch CA, Juhász A, Bajnok L, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017;27(6):571-580. doi: 10.1016/j.numecd.2017.02.007</mixed-citation><mixed-citation xml:lang="en">Csongrádi É, Káplár M, Nagy B Jr, Koch CA, Juhász A, Bajnok L, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr Metab Cardiovasc Dis. 2017;27(6):571-580. doi: 10.1016/j.numecd.2017.02.007</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Everson-Rose SA, Barinas-Mitchell EJM, El Khoudary SR, Huang HH, Wang Q, Janssen I, et al. Adipokines and subclinical cardiovascular disease in post-menopausal women: Study of women’s health across the nation. J Am Heart Assoc. 2021;10(7):e019173. doi: 10.1161/JAHA.120.019173</mixed-citation><mixed-citation xml:lang="en">Everson-Rose SA, Barinas-Mitchell EJM, El Khoudary SR, Huang HH, Wang Q, Janssen I, et al. Adipokines and subclinical cardiovascular disease in post-menopausal women: Study of women’s health across the nation. J Am Heart Assoc. 2021;10(7):e019173. doi: 10.1161/JAHA.120.019173</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Varma B, Ogunmoroti O, Ndumele CE, Zhao D, Szklo M, Sweeney T, et al. Higher leptin levels are associated with coronary artery calcium progression: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabet Epidemiol Manag. 2022;6:100047. doi: 10.1016/j.deman.2021.100047</mixed-citation><mixed-citation xml:lang="en">Varma B, Ogunmoroti O, Ndumele CE, Zhao D, Szklo M, Sweeney T, et al. Higher leptin levels are associated with coronary artery calcium progression: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabet Epidemiol Manag. 2022;6:100047. doi: 10.1016/j.deman.2021.100047</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Raman P, Khanal S. Leptin in atherosclerosis: Focus on macrophages, endothelial and smooth muscle cells. Int J Mol Sci. 2021;22(11):5446. doi: 10.3390/ijms22115446</mixed-citation><mixed-citation xml:lang="en">Raman P, Khanal S. Leptin in atherosclerosis: Focus on macrophages, endothelial and smooth muscle cells. Int J Mol Sci. 2021;22(11):5446. doi: 10.3390/ijms22115446</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012;14(11):1265-1275. doi: 10.1093/eurjhf/hfs111</mixed-citation><mixed-citation xml:lang="en">Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012;14(11):1265-1275. doi: 10.1093/eurjhf/hfs111</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Puurunen VP, Kiviniemi A, Lepojärvi S, Piira OP, Hedberg P, Junttila J, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Ann Med. 2017;49(5):448-454. doi: 10.1080/07853890.2017.1301678</mixed-citation><mixed-citation xml:lang="en">Puurunen VP, Kiviniemi A, Lepojärvi S, Piira OP, Hedberg P, Junttila J, et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease. Ann Med. 2017;49(5):448-454. doi: 10.1080/07853890.2017.1301678</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bickel C, Schnabel RB, Zeller T, Lackner KJ, Rupprecht HJ, Blankenberg S, et al. Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: Results from the AtheroGene study. Biomarkers. 2017;22(3-4):210-218. doi: 10.3109/1354750X.2015.1130745</mixed-citation><mixed-citation xml:lang="en">Bickel C, Schnabel RB, Zeller T, Lackner KJ, Rupprecht HJ, Blankenberg S, et al. Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: Results from the AtheroGene study. Biomarkers. 2017;22(3-4):210-218. doi: 10.3109/1354750X.2015.1130745</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ait Eldjoudi D, Cordero Barreal A, Gonzalez-Rodríguez M, Ruiz-Fernández C, Farrag Y, Farrag M, et al. Leptin in osteoarthritis and rheumatoid arthritis: Player or bystander? Int J Mol Sci. 2022;23(5):2859. doi: 10.3390/ijms23052859</mixed-citation><mixed-citation xml:lang="en">Ait Eldjoudi D, Cordero Barreal A, Gonzalez-Rodríguez M, RuizFernández C, Farrag Y, Farrag M, et al. Leptin in osteoarthritis and rheumatoid arthritis: Player or bystander? Int J Mol Sci. 2022;23(5):2859. doi: 10.3390/ijms23052859</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YH, Bae SC. Circulating leptin level in rheumatoid arthritis and its correlation with disease activity: A meta-analysis. Z Rheumatol. 2016;75(10):1021-1027. doi: 10.1007/s00393-016-0050-1</mixed-citation><mixed-citation xml:lang="en">Lee YH, Bae SC. Circulating leptin level in rheumatoid arthritis and its correlation with disease activity: A meta-analysis. Z Rheumatol. 2016;75(10):1021-1027. doi: 10.1007/s00393-016-0050-1</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CY, Tsai TY, Huang YC. Insulin resistance and serum levels of adipokines in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Lupus. 2020;29(9):1078-1084. doi: 10.1177/0961203320935185</mixed-citation><mixed-citation xml:lang="en">Kuo CY, Tsai TY, Huang YC. Insulin resistance and serum levels of adipokines in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Lupus. 2020;29(9):1078-1084. doi: 10.1177/0961203320935185</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Rabih AM, et al. Role of leptin in systemic lupus erythematosus: Is it still a mystery? Cureus. 2022;14(7):e26751. doi: 10.7759/cureus.26751</mixed-citation><mixed-citation xml:lang="en">Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Rabih AM, et al. Role of leptin in systemic lupus erythematosus: Is it still a mystery? Cureus. 2022;14(7):e26751. doi: 10.7759/cureus.26751</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9): 2569-2581. doi: 10.1002/art.27584</mixed-citation><mixed-citation xml:lang="en">Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9): 2569-2581. doi: 10.1002/art.27584</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation><mixed-citation xml:lang="en">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi: 10.1007/BF00280883</mixed-citation><mixed-citation xml:lang="en">Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi: 10.1007/BF00280883</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, de Armas-Rillo L, Ojeda S, Erausquin C, et al. Higher prevalence and degree of insulin resistance in patients with rheumatoid arthritis than in patients with systemic lupus erythematosus. J Rheumatol. 2021;48(3):339-347. doi: 10.3899/jrheum.200435</mixed-citation><mixed-citation xml:lang="en">Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, de Armas-Rillo L, Ojeda S, Erausquin C, et al. Higher prevalence and degree of insulin resistance in patients with rheumatoid arthritis than in patients with systemic lupus erythematosus. J Rheumatol. 2021;48(3):339-347. doi: 10.3899/jrheum.200435</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Santos MJ, Vinagre F, Silva JJ, Gil V, Fonseca JE. Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of female patients. Acta Reumatol Port. 2010;35(3):325-332.</mixed-citation><mixed-citation xml:lang="en">Santos MJ, Vinagre F, Silva JJ, Gil V, Fonseca JE. Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: A comparative study of female patients. Acta Reumatol Port. 2010;35(3):325-332.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-2112. doi: 10.1002/art.23600</mixed-citation><mixed-citation xml:lang="en">Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-2112. doi: 10.1002/art.23600</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L, Espinel-Bermudez MC, Garcia-Benavides L, Perez-Guerrero E, et al. Fasting triglycerides and glucose index: A useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus. Diabetol Metab Syndr. 2019;11:95. doi: 10.1186/s13098-019-0495-x</mixed-citation><mixed-citation xml:lang="en">Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L, Espinel-Bermudez MC, Garcia-Benavides L, Perez-Guerrero E, et al. Fasting triglycerides and glucose index: A useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus. Diabetol Metab Syndr. 2019;11:95. doi: 10.1186/s13098-019-0495-x</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Guimarães MFBR, de Andrade MVM, Machado CJ, Vieira ÉLM, Pinto MRDC, et al. Leptin as an obesity marker in rheumatoid arthritis. Rheumatol Int. 2018;38(9):1671-1677. doi: 10.1007/s00296-018-4082-5</mixed-citation><mixed-citation xml:lang="en">Guimarães MFBR, de Andrade MVM, Machado CJ, Vieira ÉLM, Pinto MRDC, et al. Leptin as an obesity marker in rheumatoid arthritis. Rheumatol Int. 2018;38(9):1671-1677. doi: 10.1007/s00296-018-4082-5</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">La Cava A. Leptin in inflammation and autoimmunity. Cytokine. 2017;98:51-58. doi: 10.1016/j.cyto.2016.10.011</mixed-citation><mixed-citation xml:lang="en">La Cava A. Leptin in inflammation and autoimmunity. Cytokine. 2017;98:51-58. doi: 10.1016/j.cyto.2016.10.011</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Federico LE, Johnson TM, England BR, Wysham KD, George MD, Sauer B, et al. Circulating adipokines and associations with incident cardiovascular disease in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(4):768-777. doi: 10.1002/acr.24885</mixed-citation><mixed-citation xml:lang="en">Federico LE, Johnson TM, England BR, Wysham KD, George MD, Sauer B, et al. Circulating adipokines and associations with incident cardiovascular disease in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(4):768-777. doi: 10.1002/acr.24885</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191</mixed-citation><mixed-citation xml:lang="en">Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Marouen S, Barnetche T, Combe B, Morel J, Daïen CI. TNF inhibitors increase fat mass in inflammatory rheumatic disease: A systematic review with meta-analysis. Clin Exp Rheumatol. 2017;35(2):337-343.</mixed-citation><mixed-citation xml:lang="en">Marouen S, Barnetche T, Combe B, Morel J, Daïen CI. TNF inhibitors increase fat mass in inflammatory rheumatic disease: A systematic review with meta-analysis. Clin Exp Rheumatol. 2017;35(2):337-343.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Toussirot E. The Interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020;10(3):107. doi: 10.3390/metabo10030107</mixed-citation><mixed-citation xml:lang="en">Toussirot E. The Interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020;10(3):107. doi: 10.3390/metabo10030107</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
